Mechanistic Insights into the Enhancement of Adeno-Associated Virus Transduction by Proteasome Inhibitors
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Proteasome inhibitors (e.g., bortezomib, MG132) are known to enhance adeno-associated virus (AAV) transduction; however, whether this results from pleotropic proteasome inhibition or off-target serine and/or cysteine protease inhibition remains unresolved. Here, we examined recombinant AAV (rAAV) effects of a new proteasome inhibitor, carfilzomib, which specifically inhibits chymotrypsin-like proteasome activity and no other proteases. We determined that proteasome inhibitors act on rAAV through proteasome inhibition and not serine or cysteine protease inhibition, likely through positive changes late in transduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another proteasome inhibitor, car fi lzomib, also enhanced AAV2 transduction in mice, however, to a lesser extent than bortezomib (68).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [68]
In the citing paper
“Both bortezomib and carfilzomib enhance rAAV2 transduction in vitro, but bortezomib is more efficacious than carfilzomib in vivo when administered by retro-orbital injection with rAAV2 (56).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [56]
Citations
Cites
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Human and mouse proteases: a comparative genomic approach
Puente, X. S., Sánchez, L. M., Overall, C. M., & López-Otín, C. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1111 · Cited by 943 · cited 1×
“Unlike other classes of proteases, active site threonine of the proteasome is the N-terminal residue of each catalytic subunit, exposing the amino group to possible reactivity (31).”
BackgroundKuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Self-citationAntitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 678 · cited 3×
“Carfilzomib, a second-generation PI, relies on this amino group to form a morpholino, covalently inhibiting cleavage (32), and so cannot inhibit other proteases (33, 34).”
BackgroundMethodProduction and characterization of adeno-associated viral vectors
Grieger, J. C., Choi, V. W., & Samulski, R. J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.207 · Cited by 581 · cited 1×
“To address the question of whether a specific PI is sufficient to enhance rAAV transduction, we utilized three PIs, MG132, bortezomib, and carfilzomib (Selleck Chemicals), and an rAAV serotype 2 (rAAV2) vector expressing luciferase or enhanced green fluorescent protein (EGFP) transgenes (35).”
MethodSelf-citationGrieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
Self-citationArastu-Kapur, S., Anderl, J. L., Kraus, M., Parlati, F., Shenk, K. D., Lee, S. J., Muchamuel, T., Bennett, M. K., Driessen, C., Ball, A. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1950 · Cited by 408 · cited 1×
“neurotoxicity (30), demonstrating the importance of off-target”
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8317 · Cited by 391 · cited 3×
“This agrees with previous results demonstrating increased nuclear localization of virus following PI treatment (6, 11, 17, 23, 26, 27) and specifically increased nucleolar localization (8).”
BackgroundResultTsubuki, S., Saito, Y., Tomioka, M., Ito, H., & Kawashima, S. (1996) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021280 · Cited by 306
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Self-citationBeck, H., Härter, M., Haß, B., Schmeck, C., & Baerfacker, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.015 · Cited by 198
Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges
Maes, M. E., Colombo, G., Schulz, R., & Siegert, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134310 · Cited by 145
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
Metadata
- Authors
- Mitchell, A. M., & Samulski, R. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2013-12
- Volume
- 87
- Issue
- 23
- Pages
- 13035-13041
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC3838122
- OpenAlex
- W2097180939
- Cited by
- 63
- References
- 47
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 9 · 2022: 7 · 2021: 4 · 2020: 9 · 2019: 8 · 2018: 7 · 2017: 4 · 2016: 4 · 2015: 2 · 2014: 3
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (5u54ar056953-05, 5U54AR056953)
- University of North Carolina at Chapel Hill
- National Institute of Allergy and Infectious Diseases (R01AI072176, R01AI080726, T32AI007419)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK084033)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (5U54AR056953, U54-AR056953)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus, AAV transduction, proteasome inhibitors, carfilzomib, bortezomib, MG132, serine protease inhibition, cysteine protease inhibition, recombinant adeno-associated virus, gene delivery
- MeSH terms
- Dependovirus, Cell Line, Chymotrypsin, Humans, Oligopeptides, Parvoviridae Infections, Transduction, Genetic, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanistic Insights into the Enhancement of Adeno-Associated Virus Transduction by Proteasome Inhibitors. https://app.cochat.ai/papers/10.1128/jvi.01826-13
- The paper
- Mitchell, A. M., & Samulski, R. J. (2013). Mechanistic Insights into the Enhancement of Adeno-Associated Virus Transduction by Proteasome Inhibitors. Journal of Virology. https://doi.org/10.1128/jvi.01826-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.